Loading...
Loading...
GALT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 10.6M |
| Operating I/L | -10.6M |
| Other Income/Expense | -0.0M |
| Interest Income | 0.0M |
| Pretax | -10.6M |
| Income Tax Expense | 19.5M |
| Net Income/Loss | -30.2M |
Galectin Therapeutics Inc. is a clinical stage biopharmaceutical company specializing in the research and development of therapies for fibrotic, cancer, and other diseases. The company's primary focus is on the development of belapectin (GR-MD-02), a galectin-3 inhibitor, currently in Phase III clinical trials for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for cancer treatment. Additionally, the company is working on GM-CT-01 for cardiac and vascular fibrosis. Galectin Therapeutics Inc. also collaborates on the research and development of small organic molecule inhibitors of galectin-3 for oral administration through its joint venture, Galectin Sciences, LLC.
